Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 7:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 771 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disease Sickle Cell Anemia Clear all
Completed No phase listed Observational Results available

Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease

NCT02410811
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cardiac magnetic resonance imaging (CMR)
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD

NCT04925492
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Positron Emission Tomography, Cu-64]-LLP2A
Radiation · Drug
Lead sponsor
Enrico Novelli
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 29, 2026, 7:37 AM EDT
Recruiting Not applicable Interventional

A Socio-ecological Approach for Improving Self-management in Adolescents With SCD

NCT06290401
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
SCThrive, SCHealthED
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 21 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Wilmington, Delaware • Atlanta, Georgia • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

NCT01419977
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Placebo, Dalteparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 29, 2026, 7:37 AM EDT
Completed No phase listed Observational

Hemoglobin Desaturation in Sickle Cell Disease

NCT03908385
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Phase 2 Interventional

A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

NCT00040677
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Low Dose ICA-17043, High dose ICA-17043, Placebo
Drug
Lead sponsor
Icagen
Industry
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Oct 29, 2026, 7:37 AM EDT
Active, not recruiting Phase 1 Interventional

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

NCT06155500
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
OTQ923
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 29, 2026, 7:37 AM EDT
Active, not recruiting Not applicable Interventional

Sickle Cell Children's Exercise Study (SuCCESs)

NCT06074198
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SuCCESs
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
6 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia

NCT00270478
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension
Interventions
Erythropoietin and Hydroxyurea
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Not applicable Interventional

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

NCT01758042
View directory record Official record
Conditions
Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Syndrome (MDS), Aplastic Anemia, AL Amyloidosis, Diamond Blackfan Anemia, Myelofibrosis, Myeloproliferative Disease, Sickle Cell Anemia, Autoimmune Diseases, Thalassemia
Interventions
Haploidentical Bone Marrow/Kidney
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 29, 2026, 7:37 AM EDT
Withdrawn Phase 2 Interventional

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

NCT01932554
View directory record Official record
Conditions
Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain, Hemoglobin SS Disease With Crisis
Interventions
Abciximab, Placebo, Intravenous hydration, Ibuprofen, Parenteral narcotic, Incentive spirometry, Supplemental oxygen
Drug · Other
Lead sponsor
St. Louis University
Other
Eligibility
5 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 29, 2026, 7:37 AM EDT
Recruiting No phase listed Observational

Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

NCT06385886
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Linkage Coordinator
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

Trial of Zileuton CR in Children and Adults With Sickle Cell Disease

NCT01136941
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Zileuton
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders

NCT00005783
View directory record Official record
Conditions
Hemoglobin SC Disease, Sickle Cell Anemia
Interventions
Recombinant-methionyl human stem cell factor
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension

NCT00352430
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Nitric Oxide/INP Pulse Delivery, Nitric Oxide/INO Pulse Delivery
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Not applicable Interventional

A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease

NCT04484272
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support])., Self-monitoring of pain, stress, and opioid use + alerts/reminders.
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Not applicable Interventional Results available

LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)

NCT03593395
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Peer Mentoring [PM], Structured Education Based Transition Program STE
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
16 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • Mobile, Alabama • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 29, 2026, 7:37 AM EDT
Not listed No phase listed Observational

DSUVIA in Patients With SCD VOC Present in the ED

NCT05388188
View directory record Official record
Conditions
Sickle-Cell Disease With Crisis
Interventions
sublingual sufentanil
Drug
Lead sponsor
Jason Wilson
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

NCT04514510
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Isoquercetin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Phase 3 Interventional

Hydroxyurea Optimization Through Precision Study

NCT03789591
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Hydroxyurea
Drug
Lead sponsor
Lifespan
Other
Eligibility
6 Months to 21 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
13
States / cities
Phoenix, Arizona • Atlanta, Georgia • Peoria, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 29, 2026, 7:37 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

NCT03132324
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
INCB059872
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Miami, Florida • Tamarac, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Oct 29, 2026, 7:37 AM EDT
Active, not recruiting Not applicable Interventional

Integrative Medicine in Pain Management in Sickle Cell Disease

NCT05045820
View directory record Official record
Conditions
Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy
Interventions
needling acupuncture, laser acupuncture
Device
Lead sponsor
Indiana University
Other
Eligibility
14 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 29, 2026, 7:37 AM EDT
Completed Phase 2 Interventional

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

NCT05861453
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Epeleuton
Drug
Lead sponsor
Afimmune
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Farmington, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 29, 2026, 7:37 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ITU512, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
9
States / cities
Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 7:37 AM EDT